Thu,30Oct2014

Adrian Hobbs PhD

Professor of Cardiovascular Pharmacology
William Harvey Heart Centre (1st Floor)
Barts & The London School of Medicine & Dentistry
Charterhouse Square
London EC1M 6BQ

T: +44 (0)207 882 5778
F: +44 (0)207 882 8403
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests
The focus of my research is the physiological and pathological actions and interactions of a family of homologous enzymes, the guanylate cyclases (GC), with emphasis on the cardiovascular system. These proteins act as receptors for nitric oxide (NO) and natriuretic peptides and exert complementary cytoprotective, anti-atherosclerotic effects on the heart and vasculature. In accord, loss of these signalling pathways, a major component of endothelial dysfunction, precipitates cardiovascular disease. My group possesses diverse expertise and employs a multi-disciplinary, molecule-to-man approach including cell and molecular biology, biochemistry, in vitro & in vivo pharmacology (including several transgenics and models of disease), and clinical studies in healthy volunteers and patients, to investigate the significance of these enzymes in health and disease.

Selected Recent Publications

  • Villar IC, Scotland RS, Khambata RS, Chan M, Duchene J, Sampaio AL, Perretti M, Ahluwalia A, Hobbs AJ. Suppression of endothelial P-selectin expression contributes to reduced cell trafficking in females: an effect independent of NO and prostacyclin. Arterioscler Thromb Vasc Biol. [2011] 31:1075-83.
  • Panayiotou CM, Baliga R, Stidwill R, Taylor V, Singer M, Hobbs AJ. Resistance to endotoxic shock in mice lacking natriuretic peptide receptor-A. Br J Pharmacol. [2010] 160:2045-54.
  • Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobbs AJ. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med. [2008] 178:861-9.

 

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.